<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00490477</url>
  </required_header>
  <id_info>
    <org_study_id>N-257</org_study_id>
    <nct_id>NCT00490477</nct_id>
  </id_info>
  <brief_title>The Effects of Polymyxin-B Protects on Sepsis Induced Kidney Dysfunction: a Randomized Clinical Trial</brief_title>
  <official_title>Polymyxin-B Hemoperfusion Inactivates Circulating Proapoptotic Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to verify whether Polymyxin-B hemoperfusion protects from renal
      dysfunction in patients with severe sepsis from gram negative infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute renal failure (ARF) is a frequent complication in sepsis, in nearly to 50% of the
      cases, and the mortality rate is higher, compare to patients with ARF alone (70% vs 45%).
      Clinical and experimental studies demonstrated the key role of apoptosis, or programmed cell
      death, in the induction of tubular and glomerular injury in the course of sepsis. Indeed, it
      has been shown that inflammatory cytokines and lipopolysaccharide (LPS) cause renal tubular
      cell apoptosis via Fas- and caspase-mediated pathways. In addition, LPS is able to alter the
      normal expression pattern of sodium, urea and glucose renal transporters and to modulate
      tubular polarity by changing the expression of tight junction proteins with consequent
      back-leakage of tubular fluid in the interstitial spaces and enhancement of the inflammatory
      process. Therefore a novel extracorporeal therapy to remove circulating LPS, using the
      Polymyxin-B fiber (PMX-B) cartridge was developed. The PMX-B cartridge is an extracorporeal
      hemoperfusion device and consists of a polystyrene-based, fibrous adsorbent on which the
      polymyxin B antibiotic is covalently immobilized as a ligand to adsorb endotoxin.

      Aim of this study is to verify whether the removal of LPS, using the PMX-B hemoperfusion
      system, protects from acute renal failure, reduces the need for Renal Replacement Therapy
      (RRT) and consequently improves the outcome in severe sepsis from gram negative infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Not Requiring Renal Replacement Therapy (RRT)</measure>
    <time_frame>28 days from the admission</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Reduction of the Number of Apoptotic Cells, Stimulated With Plasma Derives From Septic Patients With Gram Negative Infection, Treated With PMX-B Hemoperfusion, on Immortalized Tubular and Glomerular Cell Cultures.</measure>
    <time_frame>72 hours after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Gram-Negative Bacterial Infections</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>CONVENTIONAL</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>POLYMYXIN-B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>an extracorporeal LPS removal</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Polymyxin -B fiber hemoperfusion system</intervention_name>
    <description>two hours treatment for two days</description>
    <arm_group_label>POLYMYXIN-B</arm_group_label>
    <other_name>PMX-B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Endotoxemia associated to severe sepsis

        Exclusion Criteria:

          -  Age &lt; 18 years old

          -  Organ transplantation

          -  Hemorrhagic shock

          -  Thrombophilia

          -  Chronic renal failure

          -  Cardiogenic shock

          -  APACHE II score &gt; 30

          -  Lack of consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>marco ranieri, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Turin, Department of Anesthesia and Intensive Care Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>marco ranieri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Turin, Department of Anesthesia and Intensive Care Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Turin, Department of anesthesia and Intensive Care Medicine</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Cantaluppi V, Assenzio B, Pasero D, Romanazzi GM, Pacitti A, Lanfranco G, Puntorieri V, Martin EL, Mascia L, Monti G, Casella G, Segoloni GP, Camussi G, Ranieri VM. Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med. 2008 Sep;34(9):1638-45. doi: 10.1007/s00134-008-1124-6. Epub 2008 May 8.</citation>
    <PMID>18463848</PMID>
  </results_reference>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2007</study_first_posted>
  <results_first_submitted>March 9, 2010</results_first_submitted>
  <results_first_submitted_qc>May 6, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 4, 2010</results_first_posted>
  <last_update_submitted>June 4, 2010</last_update_submitted>
  <last_update_submitted_qc>June 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>V. M. Ranieri, MD</name_title>
    <organization>University of Turin</organization>
  </responsible_party>
  <keyword>acute renal failure</keyword>
  <keyword>lipopolysaccharide</keyword>
  <keyword>tubular apoptosis</keyword>
  <keyword>Polymyxin-B fiber</keyword>
  <keyword>Severe sepsis from gram negative infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Gram-Negative Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyxins</mesh_term>
    <mesh_term>Polymyxin B</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Conventional Treatment (CONV)</title>
          <description>patients with Gram-negative severe sepsis who received standard care according to Surviving Sepsis Campaign guidelines</description>
        </group>
        <group group_id="P2">
          <title>Polymyxin-B Hemoperfusion Treatment (PMX-B)</title>
          <description>patients with Gram-negative severe sepsis treated with standard therapy, according to the Surviving Sepsis Campaign, and an extracorporeal therapy with a PMX-B filter that could remove LPS</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Conventional Treatment (CONV)</title>
          <description>patients with Gram-negative severe sepsis who received standard care according to Surviving Sepsis Campaign guidelines</description>
        </group>
        <group group_id="B2">
          <title>Polymyxin-B Hemoperfusion Treatment (PMX-B)</title>
          <description>patients with Gram-negative severe sepsis treated with standard therapy, according to the Surviving Sepsis Campaign, and an extracorporeal therapy with a PMX-B filter that could remove LPS</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="13"/>
                    <measurement group_id="B2" value="61" spread="10"/>
                    <measurement group_id="B3" value="60" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Not Requiring Renal Replacement Therapy (RRT)</title>
        <time_frame>28 days from the admission</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conventional Treatment (CONV)</title>
            <description>patients with Gram-negative severe sepsis who received standard care according to Surviving Sepsis Campaign guidelines</description>
          </group>
          <group group_id="O2">
            <title>Polymyxin-B Hemoperfusion Treatment (PMX-B)</title>
            <description>patients with Gram-negative severe sepsis treated with standard therapy, according to the Surviving Sepsis Campaign, and an extracorporeal therapy with a PMX-B filter that could remove LPS</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Not Requiring Renal Replacement Therapy (RRT)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Reduction of the Number of Apoptotic Cells, Stimulated With Plasma Derives From Septic Patients With Gram Negative Infection, Treated With PMX-B Hemoperfusion, on Immortalized Tubular and Glomerular Cell Cultures.</title>
        <time_frame>72 hours after randomization</time_frame>
        <posting_date>04/2007</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Conventional Treatment (CONV)</title>
          <description>patients with Gram-negative severe sepsis who received standard care according to Surviving Sepsis Campaign guidelines</description>
        </group>
        <group group_id="E2">
          <title>Polymyxin-B Hemoperfusion Treatment (PMX-B)</title>
          <description>patients with Gram-negative severe sepsis treated with standard therapy, according to the Surviving Sepsis Campaign, and an extracorporeal therapy with a PMX-B filter that could remove LPS</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>V. M. Ranieri, MD</name_or_title>
      <organization>University of Turin, Italy</organization>
      <phone>00390116334001</phone>
      <email>marco.ranieri@unito.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

